Beyond Cardio-Renal Benefits of SGLT2 Inhibitors & GLP-1 RAs: Why Aren’t Neuropathy Outcomes Included in Current Major Outcomes Trials?
Level 3, Ernest N. Morial Convention Center
Q&A with Hertzel C. Gerstein, MD, MSc, FRCPC
What is your presentation about?
I will review the following: a) What is an “outcome” and what are outcomes trials? b) How are secondary and other outcomes chosen for such trials? c) Which neuropathy outcomes could be added to such trials? d) Which neuropathy outcomes have been added to the GLP-1RA and SGLT2i trials? The presentation may be of interest to budding trialists thinking about neuropathy and how to address the issues.
What makes this topic important in 2022?
It is important to understand what sorts of outcomes and clinical measures are most suited to inclusion in large outcomes trials, and which are better suited for smaller trials that are focused on measurements and clinical variables versus clinically important outcomes.
How did you become involved with this area of diabetes research or care?
I am an endocrinologist, clinical trialist and methodologist who has designed and led many major cardiovascular outcomes trials in people with type 2 diabetes. My focus has been to create a strong outcomes- evidence base for diabetes care, upon which clinical practice can securely be based.
What are you most looking forward to at the 82nd Scientific Sessions?
Being there in person and interacting in 3 dimensions with my friends and colleagues.